$LEGN News

JP Morgan Reinstates Neutral on Legend Biotech, Announces $35 Price Target

RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $63

Legend Biotech Commences $225M Offering Of Its American Depositary Shares

Reported Sunday, Legend Biotech's LB2501 In Vivo CD19/CD20 Dual-Targeting CAR-T Achieves 100% ORR And 83.3% CR Rate At Dose Level 2 In Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

UBS Maintains Buy on Legend Biotech, Raises Price Target to $49

Legend Biotech Jumps 42% On New Data -- Here's What Comes Next

HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $65

Legend's Cancer-Fighter Notches Elusive 100% Success Rate; What's Next?

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Legend Biotech Reports 100% Response Rate And 83% Complete Remission Rate In Phase 1 Trial Of LB2501 In Vivo Dual-Targeting CAR-T Therapy For Relapsed/Refractory B-Cell Lymphoma

Legend Biotech CARVYKTI Data And Adoption Trends Meet Depressed Share Price

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

Legend Biotech Announces First-In-Human Clinical Data For LB2102; Data, Presented At 2026 ASCO, Support Clinical Potential Of CAR-T Cell Therapy In Solid Tumors

Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript

Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use

Legend Biotech (LEGN) Nears Adjusted Profitability This Year Amid Continued CARVYKTI Growth

Legend Biotech Announces Presentations at ASCO 2026

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $50 Price Target

A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals

Legend Biotech Corporation 2026 Q1 - Results - Earnings Call Presentation